In addition, Reardon et al. applied the combination of anti-CTLA-4 and anti-PD-1 therapy in glioma mouse models and cured 75% of the mice; moreover, these mice developed robust immune memory response (32). The gene discussed is CTLA4; the disease is central nervous system cancer.